A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 118 participants.
Also called NCT07379333
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 118 participants
- Registry
-
NCT07379333
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT07379333. Randomized; double masking; primary purpose treatment. Start 2026-04-13 (actual); primary completion 2027-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- HM11260C
- Intervention (Drug)
- Placebo
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct07379333- Content hash
9a90964b8a20fe0e0223a1ae3c72fe16bd59ed1df9b80084ca1fa0f8f9bb0cf4